Limits...
Change of SPARC expression after chemotherapy in gastric cancer.

Gao YY, Han RB, Wang X, Ge SH, Li HL, Deng T, Liu R, Bai M, Zhou LK, Zhang XY, Ba Y, Huang DZ - Cancer Biol Med (2015)

Bottom Line: Immunohistochemistry was used to analyze SPARC expression in 132 GC cases (including 54 cases with preoperative chemotherapy and 78 cases without preoperative chemotherapy).High SPARC expression was correlated with invasion depth, lymph node, and TNM stage.For 54 patients with preoperative chemotherapy, gross type, histology, depth of invasion, lymph node, TNM stage, and SPARC expression were related to overall survival.

View Article: PubMed Central - PubMed

Affiliation: Department of Gastrointestinal Medical Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China.

ABSTRACT

Objective: The expression of tumor biomarkers may change after chemotherapy. However, whether secreted protein acidic and rich in cysteine (SPARC) expression changes after chemotherapy in gastric cancer (GC) is unclear. This study investigated the influence of chemotherapy on SPARC expression in GC.

Methods: Immunohistochemistry was used to analyze SPARC expression in 132 GC cases (including 54 cases with preoperative chemotherapy and 78 cases without preoperative chemotherapy). SPARC expression of postoperative specimens with and without preoperative chemotherapy was assessed to analyze the influence of chemotherapy on SPARC expression.

Results: SPARC was highly expressed in GC compared with the desmoplastic stroma surrounding tumor cells and noncancerous tissues. High SPARC expression was correlated with invasion depth, lymph node, and TNM stage. After chemotherapy, a lower proportion of high SPARC expression was observed in patients with preoperative chemotherapy than in the controls. For 54 patients with preoperative chemotherapy, gross type, histology, depth of invasion, lymph node, TNM stage, and SPARC expression were related to overall survival. Further multivariate analysis showed that lymph node, histology, and SPARC expression after chemotherapy were independent prognostic factors.

Conclusion: SPARC expression may change after chemotherapy in GC. SPARC expression should be reassessed for patients with GC after chemotherapy.

No MeSH data available.


Related in: MedlinePlus

Overall survival of GC patients without preoperative chemotherapy according to the SPARC expression. Kaplan-Meier curves with univariate analyses (log-rank) for 78 GC patients without preoperative chemotherapy stratified as SPARC low expression group and SPARC high expression group; P=0.661. SPARC, secreted protein, acidic and rich in cysteine; GC, gastric cancer.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4383841&req=5

f3: Overall survival of GC patients without preoperative chemotherapy according to the SPARC expression. Kaplan-Meier curves with univariate analyses (log-rank) for 78 GC patients without preoperative chemotherapy stratified as SPARC low expression group and SPARC high expression group; P=0.661. SPARC, secreted protein, acidic and rich in cysteine; GC, gastric cancer.

Mentions: The overall cumulative 2-year survival rate of 132 GC patients (including those in group A and group B) was 64.1% in the low SPARC expression group and 60.6% in the high SPARC expression group (P=0.193). Further analysis showed that, in 78 GC patients without preoperative chemotherapy (group B), SPARC expression did not correlate with the prognosis (P=0.661) (Figure 3). However, in 54 GC patients with preoperative chemotherapy (group A), SPARC expression after chemotherapy correlated with the prognosis. The cumulative 1-, 2-, 3-year survival rates were 81.8%, 72.7%, and 56.7%, respectively, in the group with low SPARC protein expression group; however, these rates were 43.5%, 27.0%, and 13.0%, respectively, in the group with high SPARC protein expression (P=0.002) (Figure 4).


Change of SPARC expression after chemotherapy in gastric cancer.

Gao YY, Han RB, Wang X, Ge SH, Li HL, Deng T, Liu R, Bai M, Zhou LK, Zhang XY, Ba Y, Huang DZ - Cancer Biol Med (2015)

Overall survival of GC patients without preoperative chemotherapy according to the SPARC expression. Kaplan-Meier curves with univariate analyses (log-rank) for 78 GC patients without preoperative chemotherapy stratified as SPARC low expression group and SPARC high expression group; P=0.661. SPARC, secreted protein, acidic and rich in cysteine; GC, gastric cancer.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4383841&req=5

f3: Overall survival of GC patients without preoperative chemotherapy according to the SPARC expression. Kaplan-Meier curves with univariate analyses (log-rank) for 78 GC patients without preoperative chemotherapy stratified as SPARC low expression group and SPARC high expression group; P=0.661. SPARC, secreted protein, acidic and rich in cysteine; GC, gastric cancer.
Mentions: The overall cumulative 2-year survival rate of 132 GC patients (including those in group A and group B) was 64.1% in the low SPARC expression group and 60.6% in the high SPARC expression group (P=0.193). Further analysis showed that, in 78 GC patients without preoperative chemotherapy (group B), SPARC expression did not correlate with the prognosis (P=0.661) (Figure 3). However, in 54 GC patients with preoperative chemotherapy (group A), SPARC expression after chemotherapy correlated with the prognosis. The cumulative 1-, 2-, 3-year survival rates were 81.8%, 72.7%, and 56.7%, respectively, in the group with low SPARC protein expression group; however, these rates were 43.5%, 27.0%, and 13.0%, respectively, in the group with high SPARC protein expression (P=0.002) (Figure 4).

Bottom Line: Immunohistochemistry was used to analyze SPARC expression in 132 GC cases (including 54 cases with preoperative chemotherapy and 78 cases without preoperative chemotherapy).High SPARC expression was correlated with invasion depth, lymph node, and TNM stage.For 54 patients with preoperative chemotherapy, gross type, histology, depth of invasion, lymph node, TNM stage, and SPARC expression were related to overall survival.

View Article: PubMed Central - PubMed

Affiliation: Department of Gastrointestinal Medical Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China.

ABSTRACT

Objective: The expression of tumor biomarkers may change after chemotherapy. However, whether secreted protein acidic and rich in cysteine (SPARC) expression changes after chemotherapy in gastric cancer (GC) is unclear. This study investigated the influence of chemotherapy on SPARC expression in GC.

Methods: Immunohistochemistry was used to analyze SPARC expression in 132 GC cases (including 54 cases with preoperative chemotherapy and 78 cases without preoperative chemotherapy). SPARC expression of postoperative specimens with and without preoperative chemotherapy was assessed to analyze the influence of chemotherapy on SPARC expression.

Results: SPARC was highly expressed in GC compared with the desmoplastic stroma surrounding tumor cells and noncancerous tissues. High SPARC expression was correlated with invasion depth, lymph node, and TNM stage. After chemotherapy, a lower proportion of high SPARC expression was observed in patients with preoperative chemotherapy than in the controls. For 54 patients with preoperative chemotherapy, gross type, histology, depth of invasion, lymph node, TNM stage, and SPARC expression were related to overall survival. Further multivariate analysis showed that lymph node, histology, and SPARC expression after chemotherapy were independent prognostic factors.

Conclusion: SPARC expression may change after chemotherapy in GC. SPARC expression should be reassessed for patients with GC after chemotherapy.

No MeSH data available.


Related in: MedlinePlus